Quarterly report pursuant to Section 13 or 15(d)

Share-Based Compensation - Summary of Activity Under Share-Based Compensation Plans (Detail)

v3.23.3
Share-Based Compensation - Summary of Activity Under Share-Based Compensation Plans (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Outstanding and nonvested, Beginning Balance, Number of Shares [1]     4,538    
Granted, Number of Shares     3,712    
Vested, Number of Shares     (1,242)    
Forfeited, Number of Shares     (496)    
Outstanding and nonvested, Ending Balance, Number of Shares [1] 6,512   6,512   4,538
Number of Shares, Expected to vest [2] 5,912   5,912    
Outstanding and nonvested, Beginning Balance, Weighted Average Grant Date Fair Value Per Share [1]     $ 33.14    
Granted, Weighted Average Grant Date Fair Value Per Share     13.83    
Vested, Weighted Average Grant Date Fair Value Per Share     38.45    
Forfeited, Weighted Average Grant Date Fair Value Per Share     25.97    
Outstanding and nonvested, Ending Balance, Weighted Average Grant Date Fair Value Per Share [1] $ 21.66   21.66   $ 33.14
Expected to vest, Ending Balance, Weighted Average Grant Date Fair Value Per Share [2] $ 20.21   $ 20.21    
Stock Appreciation Rights (SARs)          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of Awards Outstanding, Beginning Balance [3]     3,074    
Granted, Number of Awards   0 1,659 0  
Exercised, Number of Awards     (25)    
Forfeited, Number of Awards [4]     (371)    
Number of Awards Outstanding, Ending Balance [3] 4,337   4,337   3,074
Number of Awards Exercisable, Ending Balance [5] 1,895   1,895    
Number of Awards Vested and expected to vest, Ending Balance [5] 4,279   4,279    
Weighted Average Exercise Price Per Award Outstanding, Beginning Balance [3]     $ 24.21    
Granted, Weighted Average Exercise Price Per Award     16.17    
Exercised, Weighted Average Exercise Price Per Award     15.22    
Forfeited, Weighted Average Exercise Price Per Award [4]     29.05    
Weighted Average Exercise Price Per Award Outstanding, Ending Balance [3] $ 20.77   20.77   $ 24.21
Exercisable, Weighted Average Exercise Price Per Award, Ending Balance [5] 27.41   27.41    
Weighted Average Exercise Price Per Award, Vested and expected to vest, Ending Balance [5] $ 20.84   $ 20.84    
Weighted Average Remaining Contractual Term Outstanding [3]     6 years 3 months 18 days   4 years 7 months 6 days
Exercisable Weighted Average Remaining Contractual Term [5]     2 years 3 months 18 days    
Weighted Average Remaining Contractual Term, Vested and expected to vest [5]     6 years 3 months 18 days    
Aggregate Intrinsic Value Outstanding [3],[6] $ 0.3   $ 0.3   $ 0.3
Exercisable, Aggregate Intrinsic Value [5],[6] 0.0   0.0    
Aggregate Intrinsic Value, Vested and expected to vest [5],[6] $ 0.3   $ 0.3    
Granted, Weighted Average Grant Date Fair Value Per Share $ 10.3   $ 7.93    
[1] Includes 520,138 performance-based restricted stock units as of both September 30, 2023 and December 31, 2022, which represents the maximum amount that can vest.
[2] Includes 68,300 performance-based restricted stock units.
[3] Includes 0.7 million and 0.8 million performance condition SARs as of September 30, 2023 and December 31, 2022, respectively
[4] Includes 0.1 million performance condition SARs
[5] Includes 0.7 million performance condition SARs
[6] The intrinsic value is the amount by which the current market value of the underlying stock exceeds the exercise price of the stock awards.